219 related articles for article (PubMed ID: 16132789)
1. History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States).
Chan JM; Latini DM; Cowan J; Duchane J; Carroll PR
Cancer Causes Control; 2005 Sep; 16(7):789-97. PubMed ID: 16132789
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.
Sadetsky N; Elkin EP; Latini DM; DuChane J; Carroll PR;
Prostate Cancer Prostatic Dis; 2008; 11(3):280-7. PubMed ID: 17893700
[TBL] [Abstract][Full Text] [Related]
3. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
4. Prostate brachytherapy: a descriptive analysis from CaPSURE.
Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
[TBL] [Abstract][Full Text] [Related]
5. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study.
Li Q; Kuriyama S; Kakizaki M; Yan H; Sone T; Nagai M; Sugawara Y; Ohmori-Matsuda K; Hozawa A; Nishino Y; Tsuji I
Cancer Causes Control; 2010 Jul; 21(7):1025-32. PubMed ID: 20228997
[TBL] [Abstract][Full Text] [Related]
6. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
[TBL] [Abstract][Full Text] [Related]
8. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
[TBL] [Abstract][Full Text] [Related]
9. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
Miller DC; Gruber SB; Hollenbeck BK; Montie JE; Wei JT
J Natl Cancer Inst; 2006 Aug; 98(16):1134-41. PubMed ID: 16912266
[TBL] [Abstract][Full Text] [Related]
10. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
[TBL] [Abstract][Full Text] [Related]
11. Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?
Phillips JJ; Hall MC; Lee WR; Clark PE
Urol Oncol; 2007; 25(3):196-200. PubMed ID: 17483015
[TBL] [Abstract][Full Text] [Related]
12. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
13. Diabetes mellitus and the risk of prostate cancer in Italy.
Tavani A; Gallus S; Bertuzzi M; Dal Maso L; Zucchetto A; Negri E; Franceschi S; Ramazzotti V; Montella M; La Vecchia C
Eur Urol; 2005 Mar; 47(3):313-7; discussion 317. PubMed ID: 15716192
[TBL] [Abstract][Full Text] [Related]
14. Diabetes and risk of prostate cancer in a prospective cohort of US men.
Rodriguez C; Patel AV; Mondul AM; Jacobs EJ; Thun MJ; Calle EE
Am J Epidemiol; 2005 Jan; 161(2):147-52. PubMed ID: 15632264
[TBL] [Abstract][Full Text] [Related]
15. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
16. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
[TBL] [Abstract][Full Text] [Related]
17. Statin drugs and risk of advanced prostate cancer.
Platz EA; Leitzmann MF; Visvanathan K; Rimm EB; Stampfer MJ; Willett WC; Giovannucci E
J Natl Cancer Inst; 2006 Dec; 98(24):1819-25. PubMed ID: 17179483
[TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
[TBL] [Abstract][Full Text] [Related]
19. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
[TBL] [Abstract][Full Text] [Related]
20. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
